Bress AP - Search Results

1

Estimated Population Health Benefits of Intensive Systolic Blood Pressure Treatment Among SPRINT-Eligible US Adults.

Derington CG, Bress AP, Berchie RO, Herrick JS, Shen J, Ying J, Greene T, Tajeu GS, Sakhuja S, Ruiz-Negrón N, Zhang Y, Howard G, Levitan EB, Muntner P, Safford MM, Whelton PK, Weintraub WS, Moran AE, Bellows BK. Derington CG, et al. Among authors: bress ap. Am J Hypertens. 2023 Aug 5;36(9):498-508. doi: 10.1093/ajh/hpad047. Am J Hypertens. 2023. PMID: 37378472

2

Author response to Brown et al characterization of free phenytoin concentrations in neurointensive care unit patients using a revised Winter-Tozer equation.

Kane SP, Bress AP, Tesoro EP. Kane SP, et al. Among authors: bress ap. Ann Pharmacother. 2013 Dec;47(12):1744. doi: 10.1177/1060028013505273. Ann Pharmacother. 2013. PMID: 24396112 No abstract available.

3

Feasibility of implementing a comprehensive warfarin pharmacogenetics service.

Nutescu EA, Drozda K, Bress AP, Galanter WL, Stevenson J, Stamos TD, Desai AA, Duarte JD, Gordeuk V, Peace D, Kadkol SS, Dodge C, Saraf S, Garofalo J, Krishnan JA, Garcia JG, Cavallari LH. Nutescu EA, et al. Among authors: bress ap. Pharmacotherapy. 2013 Nov;33(11):1156-64. doi: 10.1002/phar.1329. Epub 2013 Jul 17. Pharmacotherapy. 2013. PMID: 23864527 Free PMC article.

4

Characterization of unbound phenytoin concentrations in neurointensive care unit patients using a revised Winter-Tozer equation.

Kane SP, Bress AP, Tesoro EP. Kane SP, et al. Among authors: bress ap. Ann Pharmacother. 2013 May;47(5):628-36. doi: 10.1345/aph.1R651. Epub 2013 Apr 19. Ann Pharmacother. 2013. PMID: 23606554

5

Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans.

Bress A, Patel SR, Perera MA, Campbell RT, Kittles RA, Cavallari LH. Bress A, et al. Pharmacogenomics. 2012 Dec;13(16):1925-35. doi: 10.2217/pgs.12.164. Pharmacogenomics. 2012. PMID: 23215885 Free PMC article.

6

Role of cytochrome P450 genotype in the steps toward personalized drug therapy.

Cavallari LH, Jeong H, Bress A. Cavallari LH, et al. Pharmgenomics Pers Med. 2011;4:123-36. doi: 10.2147/PGPM.S15497. Epub 2011 Nov 7. Pharmgenomics Pers Med. 2011. PMID: 23226058 Free PMC article.

7

Evaluation of dabigatran bleeding adverse reaction reports in the FDA adverse event reporting system during the first year of approval.

McConeghy KW, Bress A, Qato DM, Wing C, Nutescu EA. McConeghy KW, et al. Pharmacotherapy. 2014 Jun;34(6):561-9. doi: 10.1002/phar.1415. Epub 2014 Mar 19. Pharmacotherapy. 2014. PMID: 24644100

8

Association of aldosterone synthase polymorphism (CYP11B2 -344T>C) and genetic ancestry with atrial fibrillation and serum aldosterone in African Americans with heart failure.

Bress A, Han J, Patel SR, Desai AA, Mansour I, Groo V, Progar K, Shah E, Stamos TD, Wing C, Garcia JG, Kittles R, Cavallari LH. Bress A, et al. PLoS One. 2013 Jul 30;8(7):e71268. doi: 10.1371/journal.pone.0071268. Print 2013. PLoS One. 2013. PMID: 23936266 Free PMC article.

9

Generalizability of SPRINT Results to the U.S. Adult Population.

Bress AP, Tanner RM, Hess R, Colantonio LD, Shimbo D, Muntner P. Bress AP, et al. J Am Coll Cardiol. 2016 Feb 9;67(5):463-72. doi: 10.1016/j.jacc.2015.10.037. Epub 2015 Nov 9. J Am Coll Cardiol. 2016. PMID: 26562046 Free PMC article. Clinical Trial.

10

Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.

King JB, Shah RU, Bress AP, Nelson RE, Bellows BK. King JB, et al. Among authors: bress ap. JACC Heart Fail. 2016 May;4(5):392-402. doi: 10.1016/j.jchf.2016.02.007. Epub 2016 Mar 30. JACC Heart Fail. 2016. PMID: 27039128 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

135 results

Search Page